Larotaxel is primarily used in the treatment of various cancers, particularly breast cancer and non-small cell lung cancer. It functions as a microtubule inhibitor, preventing cancer cells from dividing and proliferating. This makes it effective in slowing tumor growth and managing metastatic disease. Larotaxel is often administered intravenously as part of combination chemotherapy regimens or as a standalone therapy, depending on the patient's condition and treatment plan. Its application is carefully monitored due to potential side effects, including neutropenia and neuropathy. Ongoing research explores its efficacy in other cancer types and its potential in overcoming drug resistance in certain tumors.